Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H ( (HK:9989) ) is now available.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has released its unaudited third quarterly report for 2025, covering the nine months ending September 30, 2025. The report, prepared in accordance with PRC Accounting Standards, was approved by the board of directors, confirming the accuracy and completeness of the financial information. This announcement underscores the company’s commitment to transparency and regulatory compliance, potentially reinforcing investor confidence and maintaining its market position.
The most recent analyst rating on (HK:9989) stock is a Sell with a HK$4.31 price target. To see the full list of analyst forecasts on Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H stock, see the HK:9989 Stock Forecast page.
More about Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating within the pharmaceutical industry. The company focuses on the production and distribution of pharmaceutical products and services, with a market presence on the Hong Kong Stock Exchange.
Average Trading Volume: 1,658,250
Technical Sentiment Signal: Buy
Current Market Cap: HK$17.59B
Learn more about 9989 stock on TipRanks’ Stock Analysis page.